Retatrutide, a weight-loss medication still in clinical development by Eli Lilly, has become the subject of widespread illicit manufacturing and distribution before completing regulatory approval processes. The drug, which has not been authorized for human use by any regulatory body, is being sold through informal channels including gyms, salons, social media platforms, and street vendors, particularly in the UK.
Experts describe this phenomenon as unusual, noting that counterfeit versions of experimental drugs at such early testing stages have rarely become so prevalent. Pharmaceutical industry observers and regulatory specialists have expressed concern about the rapid normalization of the product’s distribution, with users openly discussing sources and sharing results on social media platforms. Eli Lilly has issued warnings that illicit versions may contain unknown ingredients, harmful contaminants, incorrect dosages, or entirely different substances.
Medical professionals report handling cases of patients experiencing serious adverse effects from the counterfeit products. Endocrinologists have treated individuals presenting with nausea, vomiting, diarrhea, and in some cases kidney failure. Some personal trainers are reportedly supplying and administering the drug to clients without proper medical oversight or dosage verification. A 20-year-old user reported experiencing severe gastrointestinal distress and bloating after administering eight times the recommended dose, nearly requiring emergency hospital care.
Retatrutide represents a novel mechanism of action compared to existing weight-loss medications currently on the market. Whereas drugs like semaglutide and tirzepatide target one or two hormone receptors, retatrutide is designed to act on three—GLP-1, GIP, and glucagon—if approved. Clinical trial researchers emphasize that legitimate testing requires comprehensive medical screening, mental health assessments, and ongoing medical supervision, protections entirely absent when users obtain counterfeit versions. Only 50% of drugs in Phase III testing stages in the US ultimately receive FDA approval, meaning retatrutide’s eventual availability remains uncertain.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI